BioMarin Pharmaceutical Inc. conducted its first-quarter 2026 earnings conference call on May 4, 2026. Company executives, including CEO Alexander Hardy, presented financial results and updates. The call included forward-looking statements and non-GAAP measures.
BioMarin Pharmaceutical Inc. (BMRN) hosted its Q1 2026 earnings conference call on May 4, 2026, at 4:30 PM EDT. Traci McCarty, Group Vice President and Head of Investor Relations, opened the session, reminding participants of forward-looking statements about the company's business prospects, financial performance, and product programs. She noted that actual results may differ due to factors like regulatory actions and market developments, as detailed in SEC filings such as 10-Q, 10-K, and 8-K reports. The company also planned to use non-GAAP financial measures, with reconciliations available in the earnings release and presentation. Key participants included Alexander Hardy, President, CEO & Director; Brian Mueller, CFO & Executive VP of Finance; Cristin Hubbard, Executive VP & Chief Commercial Officer; and Gregory Friberg, Executive VP and Chief Research & Development Officer. Analysts from firms like Goldman Sachs, Stifel, Evercore, TD Cowen, Raymond James, Leerink Partners, and BofA Securities joined the call. The presentation followed standard operator instructions and was recorded.